Will the 'Unvaxxed' Have the Last Laugh? For over a year

New Post Public Reply Private Reply Replies (0) Message Board
Rusty
352
Will the 'Unvaxxed' Have the Last Laugh?

For over a year now, the messaging from our “health experts” and government leaders has been as dreary as it has been monotonal: Take the covid “vaccine” or die.

That talking point was reiterated by President Biden* just a few weeks ago when he warned the “unvaxxed” would face “a winter of severe disease and death.” And that was before New Jersey’s resident rodent meteorologist, Milltown Mel, shuffled off this mortal coil just prior to Groundhog Day. So I guess that means, in New Jersey at least, another six weeks of severe disease and death.

Originally, of course, we were told the mRNA injections would prevent people from contracting the disease. “If you get vaccinated, you won’t get covid” was the mantra recited for months, in various forms and multiple forums, by Drs. Fauci, Walensky, and Murthy, President Biden*, and many others. We were also assured that sufficiently jabbed people don’t spread the virus, with Fauci claiming the injections constitute a “dead end for covid.”

It's important not to forget those statements, as the same people now insist they never promised any such thing. Perhaps that’s because, in the face of overwhelming evidence, they’ve been forced to admit jabbed people can and do get covid and can and do give it to others. Said Walensky just a few weeks ago, “what [the vaccines] can’t do anymore is prevent transmission.” Even Pfizer CEO Albert Bourla was forced to acknowledge that his products now offer “limited, in any, protection.”

But what about the vaunted “death benefit” from the mRNA injections? They still protect against serious illness and death, right? Well, yes, that does seem to be the case—but the effect is waning fast. Moreover, the claim itself comes with several asterisks.

There have always been questions about how we count “covid deaths,” as both the CDC and the UK’s National Health Service have recently acknowledged. But if anything, those problems have been amplified in the way we differentiate between “vaccinated” and “unvaccinated” deaths.

For one thing, the most commonly cited number to prove “vaccine efficacy”—“90 percent of covid deaths are among the unvaccinated”—is fundamentally flawed because it goes back to the earliest days of the injections when almost no one had gotten them. Obviously, nearly all who died of (or with) covid in January and February of 2021 were “unvaccinated.”

Moreover, our health officials have been engaged for over a year in a kind of statistical sleight of hand, categorizing people who have taken the injections as “unvaccinated” up until 14 days after their second shot, which means at least five or six weeks have passed since their first shot. In doing so, they ignore evidence that the shots actually make people more susceptible to the virus in the short term. So if you contract covid after getting both shots, but prior to the closing of the 14-day window, and then die, you are considered an “unvaccinated” death. (They’re playing this same trick with the booster shots, too.)

This method also does not account for those who die as a result of immediate adverse reactions to the shots. Such deaths are generally numbered among the “unvaccinated,” even though it was the “vaccine” that killed them. But that’s a topic for another day.

Another fact the Covidians like to conveniently gloss over is that most people who die from covid, still, are elderly and/or infirm. In many cases, they’re already at death’s door, too sick even to be injected, which for them would simply hasten the inevitable with no appreciable benefit. Yet when they do die, they’re chalked up as “unvaccinated.” That clearly skews the numbers.

Unfortunately for the vaccinators, the “death benefit” narrative is beginning to erode, much like the “you won’t get covid” narrative before it. The latest statistics out of the UK (whose numbers are more accurate and honest than ours, although still not completely transparent), as broken down by Igor Chudov on Substack, show protection against death waning in all age groups, week over week, by an average of seven percent. Worst is the 40-49 age group, which just saw a 12 percent decline.

In addition, the director of the coronavirus ward at Israel’s Ichilov Hospital, Prof. Jacob Giris, reports that at his institution, “between 70 and 80 percent of…severe cases are vaccinated” and boosted, with “at least three injections.”

He goes on to conclude, in an interview with a local news channel, that “the vaccine has no significance regarding severe illness.”


And then there’s this: a new study out of The Netherlands claims to have determined the reason for the apparent “death benefit”—and it’s not good news. As you may recall, way back at the beginning of the pandemic, we were told it's often not the coronavirus itself that kills but rather the immune system’s extreme overreaction to the virus—the “cytokine storm.” Remember that?


Well, the Dutch researchers think they know why the injections seem to prevent some deaths: because they impede the immune system’s response to the point where such extreme reactions are less likely. From the study: “We observed a significant reduction in the production of IFN-a (Interferon-alpha, a primary cytokine) secreted after…the administration of the second dose of the vaccine. This may hamper the initial innate immune response against the virus.”

So, yeah. There you go. The injections might—emphasis on might—provide some short-term protection against serious illness and death, although that benefit appears to be disappearing fast. But at what cost? The potentially permanent suppression of your immune system?


https://townhall.com/columnists/robjenkins/20...PPKJHDQMcY
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Frontera Energy's Q3 Results Call: Key Insights Ahead

Updated Category News Views 144

What to Expect from Frontera’s Upcoming Call Frontera Energy’s got a date with the earnings table, and it’s set for November 11. The story here is about anticipation, folks. This Canadian energy player will lay its third-quarter results bare soon as trading wraps up. They’ll be breaking the nitty-gritty down in a call with the analysts that follows the next day,...

Continue Reading
Hanwha's Big Bet: Tokenizing Real-World Assets with Chainlink

Updated Category News Views 39

Hanwha and Chainlink: A Game Changer in Tokenization What do Hanwha Investment & Securities, a heavyweight in Korea's finance scene, and Chainlink, the wizard of onchain finance, think they're up to? They're buddies now, locked and loaded, to tokenize real-world assets (RWAs). They're not just shaking hands; they're aiming to jiggle the global finance bedrock....

Continue Reading
W.E.B. Du Bois Documentary Ignites Voting Rights Discussion

Updated Category News Views 25

The Lasting Resonance of W.E.B. Du Bois When we think about the fight for democracy, the legacy of W.E.B. Du Bois is bound to pop up. Thanks to director Rita Coburn, his legacy gets a full-on showcase through her latest documentary, W.E.B. Du Bois: Rebel With a Cause. This piece isn't just about looking back—it's about turning history into a mirror reflecting today's...

Continue Reading
Human Judgment Crucial Amid AI Growth in Courts

Updated Category News Views 127

AI in the Justice System: Balancing Potential and Pitfalls You know, when it comes to upholding justice, there's a line between what machines can handle and what only a human can bring to the gavel. Chief Justice Sundaresh Menon of Singapore threw the spotlight on this at an event in Brisbane, hammering home the need for good ole human intuition in the courtroom even as...

Continue Reading
FDA Greenlights VELO: A Turning Point for Reynolds?

Updated Category News Views 33

FDA Decision: A Big Win for Reynolds American Boy, am I seeing a shift in the winds. The FDA's green light for VELO nicotine pouches adds a fresh feather to Reynolds American's cap. In a gritty industry like tobacco, getting FDA's nod ain't just about safety; it’s a strategic leg up against traditional smoke. My gut tells me this isn't just about keeping pace. It's...

Continue Reading
Food Emulsifiers Surge: Market to Hit $5.60B by 2031

Updated Category News Views 72

Forecasting Growth in Food Emulsifiers Picture this: the food emulsifiers market is steaming ahead, anticipating a thunderous boom from $4.43 billion in 2026 to a whopping $5.60 billion by 2031. According to recent estimates, that's a steady clip at a CAGR of 4.8%. If you're thinking that's just more industry chatter, let's peel back the layers and see what makes this...

Continue Reading
Novelis Readies for Q2 Earnings Amid Global Market Focus

Updated Category News Views 36

Amid the ever-turbulent waves of industrial demand and environmental expectations, Novelis Inc. is set to lay bare its fiscal cards for Q2 of 2027. Circle November 5 on your calendar—this is when Steve Fisher and Dev Ahuja aim to sift through the heaps, scrutinize numbers, and spell out their game plan for investors via a conference call. Get your coffee ready for this...

Continue Reading
AbbVie's Q3 2026: Strong Performance and Bold Moves

Updated Category News Views 28

A Deep Dive into AbbVie's Q3 2026 Numbers Bruised and battered from the ebbs and flows of the market, AbbVie (NYSE:ABBV) decided to show up in swagger mode for the third quarter of 2026. They doubled their diluted EPS year over year with a GAAP figure hitting $2.37, backed by an adjusted EPS of $3.82. You're seeing the fruits of savvy expansions and a portfolio that seems...

Continue Reading
Triskell's 2026 Update: AI Leverages Portfolio Data

Updated Category News Views 58

Triskell's Strategic AI Leap Forward Forget the old grind of manual data tinkering—Triskell Software's latest AI enhancements in their 2026 SP2 release are setting a new stage. The Spain-based outfit is tweaking their Project Portfolio Management tools under the hood to suit modern instincts. It seems like portfolio management is getting a brain boost with some added AI...

Continue Reading
Cohen Veterans Network Invites Americans to Honor Veterans

Updated Category News Views 40

Cohen Veterans Network Launches "Call to Honor" Initiative The struggle to adequately acknowledge the sacrifices of veterans isn't new, but Cohen Veterans Network (CVN) is trying something a little different this time. "Call to Honor," a gratitude hotline, isn't just another method of saying "thanks"—it's a more profound communication channel for Americans to express...

Continue Reading

Top 5 Most Recently Viewed Articles

Jack Dorsey Calls Tesla's Cybertruck the Ultimate Machine

Updated Category News Views 286

Jack Dorsey Hails the Cybertruck as a Superior Electric Vehicle Recently, Block Inc. CEO and Twitter co-founder Jack Dorsey expressed admiration for Tesla Inc.'s innovation by referring to the Cybertruck as "the best robot out there." This comment resonates with the growing anticipation surrounding Tesla's electric utility truck, which stands out for its advanced...

Continue Reading
Planview Enhances Software Delivery with Plutora Acquisition

Updated Category News Views 153

Planview's Strategic Acquisition of Plutora Planview has made a major move by acquiring Plutora, a step aimed at enriching its product offerings. As a leader in Strategic Portfolio Management (SPM) and Digital Product Development (DPD), Planview is eager to harness Plutora's advanced Value Stream Management (VSM) solutions to bring great value to its customers. Reasons...

Continue Reading
SoFi Innovates Payments with Galileo's Cyberbank Core Technology

Updated Category News Views 287

SoFi Technologies Transforming Payment Services SoFi Technologies, Inc. (NASDAQ: SOFI) has recently announced a significant upgrade to its payment service offerings by adopting Galileo’s advanced cloud-based Cyberbank Core. This powerful technology is set to enhance a variety of payment solutions, including debit, prepaid, ACH, and wire transactions for its commercial...

Continue Reading
Top Financial Headlines: Key Insights from September 2025

Updated Category News Views 258

Key Financial Developments: A September Recap September proved to be a pivotal month in the finance sector, showcasing a variety of noteworthy press releases. This recap focuses on significant developments that shaped the industry, highlighting major mergers, innovative funding strategies, and the ongoing transformation fueled by AI technology. Major Mergers and...

Continue Reading
Lerøy Seafood Group ASA Announces Ex-Dividend Information Today

Updated Category News Views 244

Ex-Dividend Announcement for Lerøy Seafood Group ASA Lerøy Seafood Group ASA has officially announced that its shares will trade ex-dividend today, meaning that shareholders will receive NOK 2.50 per share. This adjustment marks an important date for investors looking to benefit from this dividend. Understanding Ex-Dividend Dates It's crucial for investors to grasp the...

Continue Reading